Kliinisen farmakologian yks.

Julkaisut 2011
Publications 2011

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Alakurtti K et al. Reproducibility of striatal and thalamic dopamine D2 receptor binding using (11C)raclopride with high-resolution positron emission tomography.
2 Elonen E et al. Syöpätaudit.
3 Fagerholm V et al. Alpha(2)-adrenoceptor regulation of blood glucose homeostasis.
4 Grönlund J. Effect of Cytochrome P450 2D6 and 3A Enzyme Inhibition on the Metabolism of Oxycodone.
5 Grönlund J et al. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: A randomized, three-phase, crossover, placebo-controlled study.
6 Grönlund J et al. Miconazole oral gel increases the exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.
7 Haarala A et al. Heart rate variability is independently associated with C-reactive protein but not with serum amyloid A. The Cardiovascular Risk in Young Finns Study.
8 Hagelberg NM et al. Interaction of oxycodone and voriconazole - a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects.
9 Hannukainen JC et al. Liver and pancreatic fat content and metabolism in healthy monozygotic twins discordant physical activity .
10 Hellin-Salmivaara A, Huupponen R. Lääkkeen rationaalinen valinta ja määrääminen.
11 Hilli J et al. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
12 Huupponen R, Hartikainen S. Monilääkitys - huono isäntä, joskus hyvä renki.
13 Huupponen R, Heinonen S. Obstetriset ja gynekologiset lääkkeet.
14 Huupponen R et al. Silmäsairaudet.
15 Huupponen R et al. Kliinisten lääketutkimusten suorittaminen ja raportointi.
16 Idänpään-Heikkilä JE, Huupponen R. Haittavaikutusten vuoksi vuosina 2005-2010 käytöstä poistuneet lääkkeet.
17 Iirola T et al. Dexmedetomidine inhibits gastric emptying and oro-caecal transit in healthy volunteers.
18 Iirola T et al. Bioavailability of dexmedetomidine after intranasal administration.
19 Juonala M et al. A longitudinal analysis on associations of adiponectin levels with metabolic syndrome and carotid artery intima-media thickness. The cardiovascular risk in young Finns study .
20 Järvelä J. Kainic Acid-induced Seizures: Inflammation and Excitotoxic Neuronal Damage in the Developing Rat Hippocampus.
21 Järvelä JT et al. Temporal profiles of age-dependent changes in cytokine mRNA expression and glial cell activation after status epilepticus in postnatal rat hippocampus.
22 Järvelä JT et al. Kainic acid-induced neurodegeneration and activation of inflammatory processes in organotypic hippocampal slice cultures: Treatment with cyclooxygenase-2 inhibitor does not prevent neuronal death.
23 Kaskinoro K et al. Wide inter-individual variability of bispectral index and spectral entropy at loss of consciousness during increasing concentrations of dexmedetomidine, propofol, and sevoflurane.
24 Kiviniemi V et al. Suboptimal use of statins at treatment initiation.
25 Kiviniemi V et al. Statiinihoito aloitetaan simvastatiinilla pienin annoksin.
26 Koivunen J et al. Amyloid PET imaging in mild cognitive impairment patients: a two year follow-up study.
27 Kopp UC et al. Dietary sodium modulates the interaction between efferent and afferent renal nerve activity by altering activation of a2-adrenoceptors on renal sensory nerves.
28 Korhonen MJ et al. Dynamics of long-term statin therapy.
29 Kurnik D et al. Genetic variations in the alpha2A-adrenoceptor are associated with blood pressure response to the agonist dexmedetomidine.
30 Laurila JMM et al. Involvement of the first transmembrane segment of human alpha2-adrenoceptros in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine.
31 Lee MS et al. The effect of age on motor deficits and cerebral glucose metabolism of Parkinson's disease.
32 Leino K et al. Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study.
33 Neuvonen PJ et al., toim. Kliininen farmakologia ja lääkehoito.
34 Noreika V et al. Consciousness lost and found: Subjective experiences in an unresponsive state.
35 Orava J et al. Different metabolic responses of human brown adipose tissue to activation by cold and insulin .
36 Peltoniemi MA et al. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
37 Posti J. Aivovammapotilaan ekstrakraniaalisen kirurgian ajoittaminen.
38 Posti JP et al. Dorsal hand vein responses to the a(1)-adrenoceptor agonist phenylephrine do not predict responses to the a(2)-adrenoceptor agonist dexmedetomidine.
39 Ruokoniemi P et al. Statin adherence and the risk of major coronary events in patients with diabetes: A nested Case-control study.
40 Ruuskanen J. Parkinson-potilas yleislääkärin vastaanotolla.
41 Uusi-Oukari M et al. Enhancement of GABAergic activity: Neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology.
42 Saczewski F et al. 3-[(Imidazolidin-2-yl)imino]indazole ligands with selectivity for the a(2)-adrenoceptor compared to the imidazoline I(1) receptor.
43 Scheinin M, Halila R. Kliinisten lääketutkimusten etiikka.
44 Scheinin NM et al. Early detection of Alzheimer disease: 11C-PiB PET in twins discordant for cognitive impairment.
45 Scheinin NM et al. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.
46 Sysi-Aho M et al. Metabolic regulation in progression to autoimmune diabetes.
47 Tertti K et al. Transfer of repaglinide in the dually perfused human placenta and role of organic anion transporting polypeptides (OATPs).
48 Upmeier E et al. Statiinien käyttö yleistyy myös vanhemmissa ikäluokissa .
49 Yamamoto K et al. Differential expression of dopaminergic cell markers in the adult zebrafis forebrain.
50 Yki-Järvinen H, Huupponen R. Diabetes.
51 Ylitalo P et al. Silmätautien kliininen farmakologia.
Julkaisutietokanta 23.11.2012 Publications Data Base 23.11.2012